BioLineRx Strengthens Patent Protection for Motixafortide
- The allowance enhances the company's intellectual property estate and extends the patent protection for motixafortide through December 2041 -
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a leading biopharmaceutical company focused on developing treatments in oncology and rare diseases, has achieved an important milestone by receiving a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). The newly granted patent titled "COMPOSITION OF BL-8040" covers the composition of motixafortide, also known as APHEXDA®/BL-8040.
The Importance of the Patent Allowance
This new patent significantly bolsters BioLineRx’s intellectual property portfolio, extending motixafortide's patent protection in the United States until December 2041. This strategic move reinforces the company's position and underscores the unique characteristics of motixafortide, which are vital for its application as a mobilization agent for patients with multiple myeloma undergoing autologous stem cell transplantation.
CEO’s Insight on the Developments
Philip Serlin, CEO of BioLineRx, expressed his satisfaction with the patent allowance, stating, "We are very pleased to significantly strengthen our motixafortide IP with this key Composition of Matter patent. This significantly extends our protection for this life-changing drug through December 2041." He emphasized that the acknowledgment by the USPTO reflects the drug's unique attributes and its potential in treating various indications, including pancreatic cancer and sickle cell disease.
Comprehensive Patent Coverage and Market Exclusivity
Alongside this recent patent, BioLineRx has secured a variety of U.S. and international patents that cover multiple aspects of motixafortide, including its composition, synthesis methods, and various uses. Additionally, the company was granted seven years of Orphan Drug market exclusivity starting from the approval date of APHEXDA® in September 2023. This exclusivity highlights its critical role in mobilizing stem cells for transplantation in multiple myeloma patients.
Outlook on Future Applications
Motixafortide has also received Orphan Drug Designation both in the United States and Europe for the treatment of pancreatic cancer. In the U.S., it is designated for treating acute myeloid leukemia (AML) as well, demonstrating the drug's wide-reaching therapeutic potential beyond just multiple myeloma.
About BioLineRx
BioLineRx, headquartered in Israel with operations in the United States, is dedicated to developing innovative biopharmaceutical therapies. Its flagship product, APHEXDA® (motixafortide), is crucial for stem cell mobilization before autologous transplantation in multiple myeloma patients. The company is also making strides in creating investigational treatments for sickle cell disease, pancreatic cancer, and a range of other solid tumors.
Innovative Approaches to Medicine
By leveraging extensive expertise in therapeutic development and commercialization, BioLineRx is actively working to ensure that its groundbreaking discoveries make it from the laboratory directly to patients who need them. As the company progresses, it aims to transform the landscape of treatment options available in oncology and rare disease contexts.
Frequently Asked Questions
What is the significance of the new patent for BioLineRx?
The new patent strengthens BioLineRx's intellectual property rights, securing protection for motixafortide in the U.S. until December 2041.
What potential applications does motixafortide have?
Motixafortide is being investigated primarily for multiple myeloma, pancreatic cancer, and sickle cell disease among other indications.
How long is the market exclusivity for motixafortide?
BioLineRx has secured seven years of Orphan Drug market exclusivity for motixafortide, which began with its FDA approval in September 2023.
Who is the CEO of BioLineRx?
Philip Serlin is the Chief Executive Officer of BioLineRx and has been influential in driving the company's strategic initiatives.
Where can I learn more about BioLineRx?
Visit their website or check their social media channels for comprehensive information on the company and its products.
